Small sized centroblasts as poor prognostic factor in follicular lymphoma - Based on artificial intelligence analysis
Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists. We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new art...
Saved in:
| Published in | Computers in biology and medicine Vol. 178; p. 108774 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Ltd
01.08.2024
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0010-4825 1879-0534 1879-0534 |
| DOI | 10.1016/j.compbiomed.2024.108774 |
Cover
| Abstract | Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists.
We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new artificial intelligence technology in relation to the clinical prognosis. Hematoxylin and eosin slides of lesions were prepared from 36 cases of follicular lymphoma before initial chemotherapy. Cases were classified into three groups by clinical course after initial treatment. The ‘excellent prognosis’ group were without recurrence or progression of follicular lymphoma within 60 months, the ‘poor prognosis’ group were those that had relapse, exacerbation, or who died due to the follicular lymphoma within 60 months, and the ‘indeterminate prognosis’ group were those without recurrence or progression but before the passage of 60 months. We created whole slide images and image patches of hematoxylin and eosin sections for all cases. We designed an object detection model specialized for centroblasts by fine-tuning YOLOv5 and segmented all centroblasts in whole slide images. The morphological characteristics of centroblasts in relation to the clinical prognosis of follicular lymphoma were analyzed. Centroblasts in follicular lymphoma of the poor prognosis group were significantly smaller in nuclear size than those in follicular lymphoma of the excellent prognosis group in the following points: median of nuclear area (p = 0.013), long length (p = 0.042), short length (p = 0.007), nuclear area of top 10 % cells (p = 0.024) and short length of top 10 % cells (p = 0.020). Cases with a mean nuclear area of <55 μm2 had poorer event-free survival than those with a mean nuclear area of ≥55 μm2 (p < 0.0123). AI methodology is suggested to be able to surpass pathologist's observation in capturing morphological features. Small-sized centroblasts will likely become a new prognostic factor of follicular lymphoma.
[Display omitted]
•We validated follicular lymphoma based on newly developed artificial intelligence analysis.•Results reveals that small centroblasts correlated with poor prognosis.•New histopathological standard for prognostic implications of follicular lymphoma was provided. |
|---|---|
| AbstractList | Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists.
We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new artificial intelligence technology in relation to the clinical prognosis. Hematoxylin and eosin slides of lesions were prepared from 36 cases of follicular lymphoma before initial chemotherapy. Cases were classified into three groups by clinical course after initial treatment. The ‘excellent prognosis’ group were without recurrence or progression of follicular lymphoma within 60 months, the ‘poor prognosis’ group were those that had relapse, exacerbation, or who died due to the follicular lymphoma within 60 months, and the ‘indeterminate prognosis’ group were those without recurrence or progression but before the passage of 60 months. We created whole slide images and image patches of hematoxylin and eosin sections for all cases. We designed an object detection model specialized for centroblasts by fine-tuning YOLOv5 and segmented all centroblasts in whole slide images. The morphological characteristics of centroblasts in relation to the clinical prognosis of follicular lymphoma were analyzed. Centroblasts in follicular lymphoma of the poor prognosis group were significantly smaller in nuclear size than those in follicular lymphoma of the excellent prognosis group in the following points: median of nuclear area (p = 0.013), long length (p = 0.042), short length (p = 0.007), nuclear area of top 10 % cells (p = 0.024) and short length of top 10 % cells (p = 0.020). Cases with a mean nuclear area of <55 μm2 had poorer event-free survival than those with a mean nuclear area of ≥55 μm2 (p < 0.0123). AI methodology is suggested to be able to surpass pathologist's observation in capturing morphological features. Small-sized centroblasts will likely become a new prognostic factor of follicular lymphoma.
[Display omitted]
•We validated follicular lymphoma based on newly developed artificial intelligence analysis.•Results reveals that small centroblasts correlated with poor prognosis.•New histopathological standard for prognostic implications of follicular lymphoma was provided. Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists. We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new artificial intelligence technology in relation to the clinical prognosis. Hematoxylin and eosin slides of lesions were prepared from 36 cases of follicular lymphoma before initial chemotherapy. Cases were classified into three groups by clinical course after initial treatment. The 'excellent prognosis' group were without recurrence or progression of follicular lymphoma within 60 months, the 'poor prognosis' group were those that had relapse, exacerbation, or who died due to the follicular lymphoma within 60 months, and the 'indeterminate prognosis' group were those without recurrence or progression but before the passage of 60 months. We created whole slide images and image patches of hematoxylin and eosin sections for all cases. We designed an object detection model specialized for centroblasts by fine-tuning YOLOv5 and segmented all centroblasts in whole slide images. The morphological characteristics of centroblasts in relation to the clinical prognosis of follicular lymphoma were analyzed. Centroblasts in follicular lymphoma of the poor prognosis group were significantly smaller in nuclear size than those in follicular lymphoma of the excellent prognosis group in the following points: median of nuclear area (p = 0.013), long length (p = 0.042), short length (p = 0.007), nuclear area of top 10 % cells (p = 0.024) and short length of top 10 % cells (p = 0.020). Cases with a mean nuclear area of <55 μm had poorer event-free survival than those with a mean nuclear area of ≥55 μm (p < 0.0123). AI methodology is suggested to be able to surpass pathologist's observation in capturing morphological features. Small-sized centroblasts will likely become a new prognostic factor of follicular lymphoma. Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists. We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new artificial intelligence technology in relation to the clinical prognosis. Hematoxylin and eosin slides of lesions were prepared from 36 cases of follicular lymphoma before initial chemotherapy. Cases were classified into three groups by clinical course after initial treatment. The 'excellent prognosis' group were without recurrence or progression of follicular lymphoma within 60 months, the 'poor prognosis' group were those that had relapse, exacerbation, or who died due to the follicular lymphoma within 60 months, and the 'indeterminate prognosis' group were those without recurrence or progression but before the passage of 60 months. We created whole slide images and image patches of hematoxylin and eosin sections for all cases. We designed an object detection model specialized for centroblasts by fine-tuning YOLOv5 and segmented all centroblasts in whole slide images. The morphological characteristics of centroblasts in relation to the clinical prognosis of follicular lymphoma were analyzed. Centroblasts in follicular lymphoma of the poor prognosis group were significantly smaller in nuclear size than those in follicular lymphoma of the excellent prognosis group in the following points: median of nuclear area (p = 0.013), long length (p = 0.042), short length (p = 0.007), nuclear area of top 10 % cells (p = 0.024) and short length of top 10 % cells (p = 0.020). Cases with a mean nuclear area of <55 μm2 had poorer event-free survival than those with a mean nuclear area of ≥55 μm2 (p < 0.0123). AI methodology is suggested to be able to surpass pathologist's observation in capturing morphological features. Small-sized centroblasts will likely become a new prognostic factor of follicular lymphoma.Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists. We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new artificial intelligence technology in relation to the clinical prognosis. Hematoxylin and eosin slides of lesions were prepared from 36 cases of follicular lymphoma before initial chemotherapy. Cases were classified into three groups by clinical course after initial treatment. The 'excellent prognosis' group were without recurrence or progression of follicular lymphoma within 60 months, the 'poor prognosis' group were those that had relapse, exacerbation, or who died due to the follicular lymphoma within 60 months, and the 'indeterminate prognosis' group were those without recurrence or progression but before the passage of 60 months. We created whole slide images and image patches of hematoxylin and eosin sections for all cases. We designed an object detection model specialized for centroblasts by fine-tuning YOLOv5 and segmented all centroblasts in whole slide images. The morphological characteristics of centroblasts in relation to the clinical prognosis of follicular lymphoma were analyzed. Centroblasts in follicular lymphoma of the poor prognosis group were significantly smaller in nuclear size than those in follicular lymphoma of the excellent prognosis group in the following points: median of nuclear area (p = 0.013), long length (p = 0.042), short length (p = 0.007), nuclear area of top 10 % cells (p = 0.024) and short length of top 10 % cells (p = 0.020). Cases with a mean nuclear area of <55 μm2 had poorer event-free survival than those with a mean nuclear area of ≥55 μm2 (p < 0.0123). AI methodology is suggested to be able to surpass pathologist's observation in capturing morphological features. Small-sized centroblasts will likely become a new prognostic factor of follicular lymphoma. Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists.We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new artificial intelligence technology in relation to the clinical prognosis. Hematoxylin and eosin slides of lesions were prepared from 36 cases of follicular lymphoma before initial chemotherapy. Cases were classified into three groups by clinical course after initial treatment. The ‘excellent prognosis’ group were without recurrence or progression of follicular lymphoma within 60 months, the ‘poor prognosis’ group were those that had relapse, exacerbation, or who died due to the follicular lymphoma within 60 months, and the ‘indeterminate prognosis’ group were those without recurrence or progression but before the passage of 60 months. We created whole slide images and image patches of hematoxylin and eosin sections for all cases. We designed an object detection model specialized for centroblasts by fine-tuning YOLOv5 and segmented all centroblasts in whole slide images. The morphological characteristics of centroblasts in relation to the clinical prognosis of follicular lymphoma were analyzed. Centroblasts in follicular lymphoma of the poor prognosis group were significantly smaller in nuclear size than those in follicular lymphoma of the excellent prognosis group in the following points: median of nuclear area (p = 0.013), long length (p = 0.042), short length (p = 0.007), nuclear area of top 10 % cells (p = 0.024) and short length of top 10 % cells (p = 0.020). Cases with a mean nuclear area of <55 μm2 had poorer event-free survival than those with a mean nuclear area of ≥55 μm2 (p < 0.0123). AI methodology is suggested to be able to surpass pathologist's observation in capturing morphological features. Small-sized centroblasts will likely become a new prognostic factor of follicular lymphoma. AbstractHistological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in assessment among hematopathologists. We aimed to perform quantitative morphological analysis of centroblasts in follicular lymphoma using new artificial intelligence technology in relation to the clinical prognosis. Hematoxylin and eosin slides of lesions were prepared from 36 cases of follicular lymphoma before initial chemotherapy. Cases were classified into three groups by clinical course after initial treatment. The ‘excellent prognosis’ group were without recurrence or progression of follicular lymphoma within 60 months, the ‘poor prognosis’ group were those that had relapse, exacerbation, or who died due to the follicular lymphoma within 60 months, and the ‘indeterminate prognosis’ group were those without recurrence or progression but before the passage of 60 months. We created whole slide images and image patches of hematoxylin and eosin sections for all cases. We designed an object detection model specialized for centroblasts by fine-tuning YOLOv5 and segmented all centroblasts in whole slide images. The morphological characteristics of centroblasts in relation to the clinical prognosis of follicular lymphoma were analyzed. Centroblasts in follicular lymphoma of the poor prognosis group were significantly smaller in nuclear size than those in follicular lymphoma of the excellent prognosis group in the following points: median of nuclear area ( p = 0.013), long length ( p = 0.042), short length ( p = 0.007), nuclear area of top 10 % cells ( p = 0.024) and short length of top 10 % cells ( p = 0.020). Cases with a mean nuclear area of <55 μm 2 had poorer event-free survival than those with a mean nuclear area of ≥55 μm 2 ( p < 0.0123). AI methodology is suggested to be able to surpass pathologist's observation in capturing morphological features. Small-sized centroblasts will likely become a new prognostic factor of follicular lymphoma. |
| ArticleNumber | 108774 |
| Author | Sonoki, Takashi Musangile, Fidele Yambayamba Hori, Yoshikazu Takahashi, Yuichi Iwamoto, Ryuta Mori, Hideo Sagan, Kanako Hosoi, Hiroki Nishikawa, Toui Murata, Shin-ichi Kojima, Fumiyoshi Matsuzaki, Ibu Nishikawa, Mizuki Mikasa, Yurina |
| Author_xml | – sequence: 1 givenname: Ryuta orcidid: 0009-0007-2649-3797 surname: Iwamoto fullname: Iwamoto, Ryuta organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 2 givenname: Toui surname: Nishikawa fullname: Nishikawa, Toui organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 3 givenname: Fidele Yambayamba orcidid: 0000-0001-5015-8437 surname: Musangile fullname: Musangile, Fidele Yambayamba organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 4 givenname: Ibu surname: Matsuzaki fullname: Matsuzaki, Ibu organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 5 givenname: Kanako surname: Sagan fullname: Sagan, Kanako organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 6 givenname: Mizuki surname: Nishikawa fullname: Nishikawa, Mizuki organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 7 givenname: Yurina surname: Mikasa fullname: Mikasa, Yurina organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 8 givenname: Yuichi surname: Takahashi fullname: Takahashi, Yuichi organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 9 givenname: Fumiyoshi surname: Kojima fullname: Kojima, Fumiyoshi organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan – sequence: 10 givenname: Yoshikazu surname: Hori fullname: Hori, Yoshikazu organization: Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan – sequence: 11 givenname: Hiroki orcidid: 0000-0002-8682-7476 surname: Hosoi fullname: Hosoi, Hiroki organization: Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan – sequence: 12 givenname: Hideo surname: Mori fullname: Mori, Hideo organization: Department of Pathology, Osaka Habikino Medical Center, Osaka, Japan – sequence: 13 givenname: Takashi surname: Sonoki fullname: Sonoki, Takashi organization: Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan – sequence: 14 givenname: Shin-ichi orcidid: 0000-0001-9862-3051 surname: Murata fullname: Murata, Shin-ichi email: smurata@wakayama-med.ac.jp organization: Department of Human Pathology, Wakayama Medical University, Wakayama, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38897149$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFTEQhoNU7Gn1L0jAG2_2OPnYk-yNaItfUPCiCt6F2Wy25pjdrMmucPz1Zjm1QkHo1cDwzMvM-84ZORnj6AihDLYM2O7VfmvjMLU-Dq7bcuCytLVS8hHZMK2aCmohT8gGgEElNa9PyVnOewCQIOAJORVaN4rJZkOW6wFDoNn_dh21bpxTbAPmOVPMdIox0SnFmzHm2Vvao51Lx4-0jyF4uwRMNByG6XsckFb0AnNRiSPFNPveW4-hwLMr7I0braM4Yjhkn5-Sxz2G7J7d1nPy9f27L5cfq6vPHz5dvr2qrFByrlzHRcOttCiAdarVUrSc1aJ2Gnu2w7rrtGtkrxC72jUglW5FI1u14whih-KcvDzqliN-Li7PZvDZln1wdHHJRoACzTlvoKAv7qH7uKSy70pppkAWnwv1_JZa2uK9mZIfMB3MX0MLoI-ATTHn5Po7hIFZszN78y87s2ZnjtmV0YvjqCuO_PIumWz9alvnk7Oz6aJ_iMjreyI2-NFbDD_cweW7m5jJ3IC5Xl9k_RAuAXTdfCsCb_4v8LAd_gDTjtJX |
| Cites_doi | 10.1007/s11760-016-0913-6 10.1093/ajcp/aqac117 10.1002/cyto.a.22432 10.1038/s41592-019-0612-7 10.1016/j.ajpath.2022.09.013 10.1111/bjh.16159 10.1111/bjh.18423 10.1182/blood.V89.11.3909 10.1038/s41375-022-01620-2 10.1111/bjh.18404 10.1200/JCO.18.00400 10.1007/BF01489419 10.1111/j.1365-2141.2012.09054.x 10.1182/blood.V85.12.3671.bloodjournal85123671 10.1111/bjh.18522 10.1182/blood.2020010263 10.1093/nar/gkad830 10.1200/JCO.2012.48.3990 10.1002/hon.2900010209 10.1200/JCO.2014.59.7534 10.1016/S2352-3026(18)30155-8 10.1016/S1470-2045(15)00169-2 10.1182/blood.V91.12.4708 10.1200/JCO.2006.09.3260 10.1016/S1470-2045(18)30102-5 |
| ContentType | Journal Article |
| Copyright | 2024 Elsevier Ltd Elsevier Ltd Copyright © 2024 Elsevier Ltd. All rights reserved. 2024. Elsevier Ltd |
| Copyright_xml | – notice: 2024 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2024 Elsevier Ltd. All rights reserved. – notice: 2024. Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 8FD FR3 JQ2 K9. M7Z NAPCQ P64 7X8 |
| DOI | 10.1016/j.compbiomed.2024.108774 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Technology Research Database Engineering Research Database ProQuest Computer Science Collection ProQuest Health & Medical Complete (Alumni) Biochemistry Abstracts 1 Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Technology Research Database ProQuest Computer Science Collection Biochemistry Abstracts 1 ProQuest Health & Medical Complete (Alumni) Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Nursing & Allied Health Premium |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0534 |
| EndPage | 108774 |
| ExternalDocumentID | 38897149 10_1016_j_compbiomed_2024_108774 S001048252400859X 1_s2_0_S001048252400859X |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- --K --M --Z -~X .1- .55 .DC .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29F 4.4 457 4G. 53G 5GY 5VS 7-5 71M 77I 7RV 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8G5 8P~ 9JN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYFN AAYWO ABBOA ABFNM ABJNI ABMAC ABMZM ABOCM ABUWG ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACIWK ACLOT ACNNM ACPRK ACRLP ACRPL ACVFH ACZNC ADBBV ADCNI ADEZE ADJOM ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AHZHX AIALX AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOUOD APXCP ARAPS ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BENPR BGLVJ BHPHI BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GBOLZ GNUQQ GUQSH HCIFZ HLZ HMCUK HMK HMO HVGLF HZ~ IHE J1W K6V K7- KOM LK8 LX9 M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- OAUVE OZT P-8 P-9 P2P P62 PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q38 R2- ROL RPZ RXW SAE SBC SCC SDF SDG SDP SEL SES SEW SPC SPCBC SSH SSV SSZ SV3 T5K TAE UAP UKHRP WOW WUQ X7M XPP Z5R ZGI ~G- ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW M0N RIG AAIAV AAYXX CITATION PUEGO AGCQF AGRNS CGR CUY CVF ECM EIF NPM 8FD FR3 JQ2 K9. M7Z P64 7X8 |
| ID | FETCH-LOGICAL-c374t-ed2392c4ca301d7b843b21535e8af16a5dd8e94f7aad5e90478b394b762a036a3 |
| IEDL.DBID | .~1 |
| ISSN | 0010-4825 1879-0534 |
| IngestDate | Thu Oct 02 10:52:42 EDT 2025 Tue Oct 07 06:20:24 EDT 2025 Thu Jun 26 01:51:24 EDT 2025 Wed Oct 01 04:08:07 EDT 2025 Sat Jul 20 16:35:19 EDT 2024 Tue Feb 25 20:08:40 EST 2025 Tue Oct 14 19:37:57 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | Copyright © 2024 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c374t-ed2392c4ca301d7b843b21535e8af16a5dd8e94f7aad5e90478b394b762a036a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-5015-8437 0000-0001-9862-3051 0000-0002-8682-7476 0009-0007-2649-3797 |
| PMID | 38897149 |
| PQID | 3081704202 |
| PQPubID | 1226355 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_3070822290 proquest_journals_3081704202 pubmed_primary_38897149 crossref_primary_10_1016_j_compbiomed_2024_108774 elsevier_sciencedirect_doi_10_1016_j_compbiomed_2024_108774 elsevier_clinicalkeyesjournals_1_s2_0_S001048252400859X elsevier_clinicalkey_doi_10_1016_j_compbiomed_2024_108774 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-01 |
| PublicationDateYYYYMMDD | 2024-08-01 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Oxford |
| PublicationTitle | Computers in biology and medicine |
| PublicationTitleAlternate | Comput Biol Med |
| PublicationYear | 2024 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Swerdlow, Campo, Harris (bib5) 2017 Alaggio, Amador, Anagnostopoulos (bib9) 2022; 36 (bib12) 2020 Mann, Berard (bib4) 1983; 1 Conconi, Ponzio, Lobetti-Bodoni (bib15) 2012; 157 Nishikawa, Iwamoto, Matsuzaki (bib10) 2022; 158 Martin, Weisenburger, Chan (bib6) 1995; 85 Kawaguchi, Shiozawa, Shimada (bib26) 2018; 11 Link, Maurer, Nowakowski (bib14) 2013; 31 Lian, Zhang, Zhou (bib24) 2024; 52 Rajamaki, Hujo, Sund (bib18) 2022; 199 (bib8) 1997; 89 Caicedo, Goodman, Karhohs (bib13) 2019; 16 Pastore, Jurinovic, Kridel (bib20) 2015; 16 Naik, Gooley, Loeb (bib21) 2022; 199 Sarkozy, Maurer, Link (bib3) 2019; 37 Casulo, Byrtek, Dawson (bib16) 2015; 33 Lennert (bib7) 1957; 35 Nishikawa, Matsuzaki, Iwamoto (bib11) 2023; 193 Zhang, Sun, Lian (bib25) 2023; 10 Kornaropoulos, Niazi, Lozanski (bib27) 2014; 85 Casulo, Dixon, Le-Rademacher (bib17) 2022; 139 Muntañola, Mozas, Mercadal (bib19) 2023; 200 Lockmer, Ren, Brodtkorb (bib23) 2020; 188 Montoto, Davies, Matthews (bib1) 2007; 25 Dogan, Du, Aiello (bib29) 1998; 91 Watanabe, Tobinai, Wakabayashi (bib2) 2018; 5 Huet, Tesson, Jais (bib22) 2018; 19 Dimitropoulos, Barmpoutis, Koletsa (bib28) 2017; 11 Rajamaki (10.1016/j.compbiomed.2024.108774_bib18) 2022; 199 Casulo (10.1016/j.compbiomed.2024.108774_bib17) 2022; 139 Muntañola (10.1016/j.compbiomed.2024.108774_bib19) 2023; 200 Swerdlow (10.1016/j.compbiomed.2024.108774_bib5) 2017 (10.1016/j.compbiomed.2024.108774_bib8) 1997; 89 Lian (10.1016/j.compbiomed.2024.108774_bib24) 2024; 52 Naik (10.1016/j.compbiomed.2024.108774_bib21) 2022; 199 Caicedo (10.1016/j.compbiomed.2024.108774_bib13) 2019; 16 Alaggio (10.1016/j.compbiomed.2024.108774_bib9) 2022; 36 Watanabe (10.1016/j.compbiomed.2024.108774_bib2) 2018; 5 Huet (10.1016/j.compbiomed.2024.108774_bib22) 2018; 19 Sarkozy (10.1016/j.compbiomed.2024.108774_bib3) 2019; 37 Lockmer (10.1016/j.compbiomed.2024.108774_bib23) 2020; 188 Nishikawa (10.1016/j.compbiomed.2024.108774_bib11) 2023; 193 (10.1016/j.compbiomed.2024.108774_bib12) 2020 Kawaguchi (10.1016/j.compbiomed.2024.108774_bib26) 2018; 11 Dimitropoulos (10.1016/j.compbiomed.2024.108774_bib28) 2017; 11 Mann (10.1016/j.compbiomed.2024.108774_bib4) 1983; 1 Lennert (10.1016/j.compbiomed.2024.108774_bib7) 1957; 35 Pastore (10.1016/j.compbiomed.2024.108774_bib20) 2015; 16 Zhang (10.1016/j.compbiomed.2024.108774_bib25) 2023; 10 Conconi (10.1016/j.compbiomed.2024.108774_bib15) 2012; 157 Link (10.1016/j.compbiomed.2024.108774_bib14) 2013; 31 Nishikawa (10.1016/j.compbiomed.2024.108774_bib10) 2022; 158 Casulo (10.1016/j.compbiomed.2024.108774_bib16) 2015; 33 Dogan (10.1016/j.compbiomed.2024.108774_bib29) 1998; 91 Montoto (10.1016/j.compbiomed.2024.108774_bib1) 2007; 25 Martin (10.1016/j.compbiomed.2024.108774_bib6) 1995; 85 Kornaropoulos (10.1016/j.compbiomed.2024.108774_bib27) 2014; 85 |
| References_xml | – volume: 36 start-page: 1720 year: 2022 end-page: 1748 ident: bib9 article-title: The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms publication-title: Leukemia – volume: 52 start-page: D552 year: 2024 end-page: D561 ident: bib24 article-title: SingPro: a knowledge base providing single-cell proteomics data publication-title: Nucleic Acids Res. – volume: 5 start-page: e520 year: 2018 end-page: e531 ident: bib2 article-title: Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial publication-title: Lancet Haematol – volume: 199 start-page: 458 year: 2022 end-page: 462 ident: bib18 article-title: Link between disease status at 24 months and mortality in follicular lymphoma publication-title: Br. J. Haematol. – volume: 199 start-page: 696 year: 2022 end-page: 706 ident: bib21 article-title: The impact of histological grade on outcomes in follicular lymphoma: an analysis of patients in the SEER database in the context of evolving disease classification and treatment publication-title: Br. J. Haematol. – volume: 10 year: 2023 ident: bib25 article-title: ANPELA: significantly enhanced quantification tool for cytometry-based single-cell proteomics publication-title: Adv. Sci. – volume: 89 start-page: 3909 year: 1997 end-page: 3918 ident: bib8 article-title: A clinical evaluation of the international lymphoma study group classification of non-hodgkin's lymphoma. The non-hodgkin's lymphoma classification Project publication-title: Blood – volume: 188 start-page: 259 year: 2020 end-page: 267 ident: bib23 article-title: M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy publication-title: Br. J. Haematol. – volume: 11 start-page: 145 year: 2017 end-page: 153 ident: bib28 article-title: Automated detection and classification of nuclei in PAX5 and H&E-stained tissue sections of follicular lymphoma publication-title: Signal, Image and Video Processing – volume: 19 start-page: 549 year: 2018 end-page: 561 ident: bib22 article-title: A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts publication-title: Lancet Oncol. – volume: 91 start-page: 4708 year: 1998 end-page: 4714 ident: bib29 article-title: Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone publication-title: Blood – volume: 139 start-page: 1684 year: 2022 end-page: 1693 ident: bib17 article-title: Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials publication-title: Blood – volume: 11 start-page: 3366 year: 2018 end-page: 3374 ident: bib26 article-title: Ki-67 expression of immunohistochemistry using computerized image analysis is a useful prognostic marker in follicular lymphomas publication-title: Int. J. Clin. Exp. Pathol. – volume: 16 start-page: 1111 year: 2015 end-page: 1122 ident: bib20 article-title: Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry publication-title: Lancet Oncol. – volume: 25 start-page: 2426 year: 2007 end-page: 2433 ident: bib1 article-title: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma publication-title: J. Clin. Oncol. – volume: 200 start-page: 306 year: 2023 end-page: 314 ident: bib19 article-title: Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome publication-title: Br. J. Haematol. – start-page: 266 year: 2017 end-page: 277 ident: bib5 article-title: WHO classification of tumours of haematopoietic and lymphoid tissues. Revised publication-title: International Agency for Research on Cancer – volume: 85 start-page: 3671 year: 1995 end-page: 3678 ident: bib6 article-title: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma publication-title: Blood – volume: 31 start-page: 3272 year: 2013 end-page: 3278 ident: bib14 article-title: Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa/MayoClinic specialized program of research excellence molecular epidemiology resource publication-title: J. Clin. Oncol. – volume: 193 start-page: 39 year: 2023 end-page: 50 ident: bib11 article-title: Use of artificial intelligence for the interpretable prediction of the pathologic diagnosis and molecular abnormalities of flat urothelial lesions publication-title: Am. J. Pathol. – volume: 37 start-page: 144 year: 2019 end-page: 152 ident: bib3 article-title: Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts publication-title: J. Clin. Oncol. – volume: 1 start-page: 187 year: 1983 end-page: 192 ident: bib4 article-title: Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method publication-title: Hematol. Oncol. – volume: 16 start-page: 1247 year: 2019 end-page: 1253 ident: bib13 article-title: Nucleus segmentation across imaging experiments: the 2018 data science bowl publication-title: Nat. Methods – volume: 158 start-page: 759 year: 2022 end-page: 769 ident: bib10 article-title: Pathologic image classification of flat urothelial lesions using pathologic criteria-based deep learning publication-title: Am. J. Clin. Pathol. – year: 2020 ident: bib12 publication-title: Ultralytics, YOLOv5 – volume: 33 start-page: 2516 year: 2015 end-page: 2522 ident: bib16 article-title: Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study publication-title: J. Clin. Oncol. – volume: 157 start-page: 188 year: 2012 end-page: 196 ident: bib15 article-title: Incidence, risk factors and outcome of histological transformation in follicular lymphoma publication-title: Br. J. Haematol. – volume: 85 start-page: 242 year: 2014 end-page: 255 ident: bib27 article-title: Histopathological image analysis for centroblasts classification through dimensionality reduction approaches publication-title: Cytometry – volume: 35 start-page: 1130 year: 1957 end-page: 1132 ident: bib7 article-title: Identification of cells of germination center in lymph node smears publication-title: Klin. Wochenschr. – year: 2020 ident: 10.1016/j.compbiomed.2024.108774_bib12 – volume: 11 start-page: 145 year: 2017 ident: 10.1016/j.compbiomed.2024.108774_bib28 article-title: Automated detection and classification of nuclei in PAX5 and H&E-stained tissue sections of follicular lymphoma publication-title: Signal, Image and Video Processing doi: 10.1007/s11760-016-0913-6 – volume: 158 start-page: 759 year: 2022 ident: 10.1016/j.compbiomed.2024.108774_bib10 article-title: Pathologic image classification of flat urothelial lesions using pathologic criteria-based deep learning publication-title: Am. J. Clin. Pathol. doi: 10.1093/ajcp/aqac117 – volume: 10 year: 2023 ident: 10.1016/j.compbiomed.2024.108774_bib25 article-title: ANPELA: significantly enhanced quantification tool for cytometry-based single-cell proteomics publication-title: Adv. Sci. – volume: 85 start-page: 242 year: 2014 ident: 10.1016/j.compbiomed.2024.108774_bib27 article-title: Histopathological image analysis for centroblasts classification through dimensionality reduction approaches publication-title: Cytometry doi: 10.1002/cyto.a.22432 – volume: 16 start-page: 1247 year: 2019 ident: 10.1016/j.compbiomed.2024.108774_bib13 article-title: Nucleus segmentation across imaging experiments: the 2018 data science bowl publication-title: Nat. Methods doi: 10.1038/s41592-019-0612-7 – volume: 193 start-page: 39 year: 2023 ident: 10.1016/j.compbiomed.2024.108774_bib11 article-title: Use of artificial intelligence for the interpretable prediction of the pathologic diagnosis and molecular abnormalities of flat urothelial lesions publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2022.09.013 – volume: 188 start-page: 259 year: 2020 ident: 10.1016/j.compbiomed.2024.108774_bib23 article-title: M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy publication-title: Br. J. Haematol. doi: 10.1111/bjh.16159 – volume: 199 start-page: 458 year: 2022 ident: 10.1016/j.compbiomed.2024.108774_bib18 article-title: Link between disease status at 24 months and mortality in follicular lymphoma publication-title: Br. J. Haematol. doi: 10.1111/bjh.18423 – volume: 89 start-page: 3909 year: 1997 ident: 10.1016/j.compbiomed.2024.108774_bib8 article-title: A clinical evaluation of the international lymphoma study group classification of non-hodgkin's lymphoma. The non-hodgkin's lymphoma classification Project publication-title: Blood doi: 10.1182/blood.V89.11.3909 – volume: 36 start-page: 1720 year: 2022 ident: 10.1016/j.compbiomed.2024.108774_bib9 article-title: The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms publication-title: Leukemia doi: 10.1038/s41375-022-01620-2 – volume: 199 start-page: 696 year: 2022 ident: 10.1016/j.compbiomed.2024.108774_bib21 article-title: The impact of histological grade on outcomes in follicular lymphoma: an analysis of patients in the SEER database in the context of evolving disease classification and treatment publication-title: Br. J. Haematol. doi: 10.1111/bjh.18404 – volume: 37 start-page: 144 year: 2019 ident: 10.1016/j.compbiomed.2024.108774_bib3 article-title: Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.00400 – volume: 35 start-page: 1130 year: 1957 ident: 10.1016/j.compbiomed.2024.108774_bib7 article-title: Identification of cells of germination center in lymph node smears publication-title: Klin. Wochenschr. doi: 10.1007/BF01489419 – volume: 157 start-page: 188 year: 2012 ident: 10.1016/j.compbiomed.2024.108774_bib15 article-title: Incidence, risk factors and outcome of histological transformation in follicular lymphoma publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.2012.09054.x – volume: 85 start-page: 3671 year: 1995 ident: 10.1016/j.compbiomed.2024.108774_bib6 article-title: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma publication-title: Blood doi: 10.1182/blood.V85.12.3671.bloodjournal85123671 – volume: 200 start-page: 306 year: 2023 ident: 10.1016/j.compbiomed.2024.108774_bib19 article-title: Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome publication-title: Br. J. Haematol. doi: 10.1111/bjh.18522 – volume: 139 start-page: 1684 year: 2022 ident: 10.1016/j.compbiomed.2024.108774_bib17 article-title: Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials publication-title: Blood doi: 10.1182/blood.2020010263 – volume: 11 start-page: 3366 year: 2018 ident: 10.1016/j.compbiomed.2024.108774_bib26 article-title: Ki-67 expression of immunohistochemistry using computerized image analysis is a useful prognostic marker in follicular lymphomas publication-title: Int. J. Clin. Exp. Pathol. – volume: 52 start-page: D552 year: 2024 ident: 10.1016/j.compbiomed.2024.108774_bib24 article-title: SingPro: a knowledge base providing single-cell proteomics data publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkad830 – volume: 31 start-page: 3272 year: 2013 ident: 10.1016/j.compbiomed.2024.108774_bib14 article-title: Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa/MayoClinic specialized program of research excellence molecular epidemiology resource publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.48.3990 – volume: 1 start-page: 187 year: 1983 ident: 10.1016/j.compbiomed.2024.108774_bib4 article-title: Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method publication-title: Hematol. Oncol. doi: 10.1002/hon.2900010209 – volume: 33 start-page: 2516 year: 2015 ident: 10.1016/j.compbiomed.2024.108774_bib16 article-title: Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.59.7534 – volume: 5 start-page: e520 year: 2018 ident: 10.1016/j.compbiomed.2024.108774_bib2 article-title: Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial publication-title: Lancet Haematol doi: 10.1016/S2352-3026(18)30155-8 – start-page: 266 year: 2017 ident: 10.1016/j.compbiomed.2024.108774_bib5 article-title: WHO classification of tumours of haematopoietic and lymphoid tissues. Revised – volume: 16 start-page: 1111 year: 2015 ident: 10.1016/j.compbiomed.2024.108774_bib20 article-title: Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00169-2 – volume: 91 start-page: 4708 year: 1998 ident: 10.1016/j.compbiomed.2024.108774_bib29 article-title: Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone publication-title: Blood doi: 10.1182/blood.V91.12.4708 – volume: 25 start-page: 2426 year: 2007 ident: 10.1016/j.compbiomed.2024.108774_bib1 article-title: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2006.09.3260 – volume: 19 start-page: 549 year: 2018 ident: 10.1016/j.compbiomed.2024.108774_bib22 article-title: A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(18)30102-5 |
| SSID | ssj0004030 |
| Score | 2.3882241 |
| Snippet | Histological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation in... AbstractHistological assessment of centroblasts is an important evaluation in the diagnosis of follicular lymphoma, but there is substantial observer variation... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 108774 |
| SubjectTerms | Adult Aged Algorithms Artificial Intelligence Chemotherapy Clinical outcomes Female Humans Internal Medicine Lymphoma Lymphoma, Follicular - pathology Male Medical prognosis Middle Aged Morphology Object recognition Other Patients Photonics Physical characteristics Prognosis Regression analysis Technology assessment |
| Title | Small sized centroblasts as poor prognostic factor in follicular lymphoma - Based on artificial intelligence analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S001048252400859X https://www.clinicalkey.es/playcontent/1-s2.0-S001048252400859X https://dx.doi.org/10.1016/j.compbiomed.2024.108774 https://www.ncbi.nlm.nih.gov/pubmed/38897149 https://www.proquest.com/docview/3081704202 https://www.proquest.com/docview/3070822290 |
| Volume | 178 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1879-0534 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004030 issn: 0010-4825 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1879-0534 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004030 issn: 0010-4825 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] - access via UTK customDbUrl: eissn: 1879-0534 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004030 issn: 0010-4825 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect (Elsevier) customDbUrl: eissn: 1879-0534 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004030 issn: 0010-4825 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-0534 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004030 issn: 0010-4825 databaseCode: AKRWK dateStart: 19700101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: ProQuest Technology Collection customDbUrl: eissn: 1879-0534 dateEnd: 20250905 omitProxy: true ssIdentifier: ssj0004030 issn: 0010-4825 databaseCode: 8FG dateStart: 20030101 isFulltext: true titleUrlDefault: https://search.proquest.com/technologycollection1 providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB5CCqWX0nedFyr06sZrSZFMT2nIdtuSXNrA3oRsyeCysZd499Ac8tszY8mbljYQ6MVgW0JipBnNoG--AXhfcNQZK_O08BibiEpmqZXCp85PMlt7ze1QM_Ls_Gh2Ib7O5XwLTsZcGIJVRtsfbPpgreOXwyjNw2XTUI4vhhIY4BAKUstiThnsQlEVgw83dzAPkfGQhoL2hlpHNE_AeBFsO6S5Y6SYCwLcKSXuO6Luc0GHo2j6DJ5GH5Idh2k-hy3fvoDHZ_GW_CWsv1_axYL1zbV3bEBfdiU6yaue2Z4tu-6KESqr7YiimYWCO6xpWU383AMslS1-4SJ3l5al7BMec451LSOpBLoJ1vzG48lspDV5BRfT0x8nszSWV0grrsQq9S5H56gSlUUld6rUgpfoAHDpta0nR1Y6p30hamWtk74gGp-SF6JE82nx3LP8NWy3XevfAuMUxWhhc0qjraQvdel4XRMXTFX7nCcwGSVqloFFw4zwsp_mbhUMrYIJq5BAMYrejFmiaNcMmvoH9FX_6uv7qKC9mZg-N5n5axMl8HHT8499-MBx98Y9YjZD8YxIEAU2S-Dd5jdqMV3N2NZ3a2qjQmn1LIE3YW9tBMW1LhQGsjv_NbVdeEJvAbu4B9urq7XfR39qVR4MCoNPPf18AI-Ov3ybnd8CPZciKg |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VIgEXBOUVKGCkXkOzsV074gQV1QLdXmilvVlO7EhB22TV7B7gwG9nJna2RaVSJa6xLVtjz0v55huAvYKjzliZp4XH3ERUMkutFD51fpLZ2mtuh56Rs5OD6Zn4OpfzLTgca2EIVhltf7Dpg7WOX_ajNPeXTUM1vphKYIJDKEgti_kduCtkrigDe__7EuchMh7qUNDg0PQI5wkgL8Jthzp3TBVzQYg7pcRNPuqmGHTwRUeP4GEMItnHcM7HsOXbHbg3i7_Jn8D6-7ldLFjf_PKODfDLrsQoedUz27Nl110wgmW1HXE0s9BxhzUtq4mge8ClssVPvOXu3LKUfUI_51jXMhJL4JtgzRUiT2Yjr8lTODv6fHo4TWN_hbTiSqxS73KMjipRWdRyp0oteIkRAJde23pyYKVz2heiVtY66Qvi8Sl5IUq0nxYdn-XPYLvtWv8CGKc0RgubUx1tJX2pS8frmshgqtrnPIHJKFGzDDQaZsSX_TCXt2DoFky4hQSKUfRmLBNFw2bQ1t9irfrXWt9HDe3NxPS5ycy1V5TAh83Kvx7iLffdHd-I2WzFM2JBFDgtgXebYVRj-jdjW9-taY4KvdWzBJ6Ht7URFNe6UJjJvvyvo72F-9PT2bE5_nLy7RU8oJEAZNyF7dXF2r_G4GpVvhmU5w_u3CLZ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Small+sized+centroblasts+as+poor+prognostic+factor+in+follicular+lymphoma+-+Based+on+artificial+intelligence+analysis&rft.jtitle=Computers+in+biology+and+medicine&rft.au=Iwamoto%2C+Ryuta&rft.au=Nishikawa%2C+Toui&rft.au=Musangile%2C+Fidele+Yambayamba&rft.au=Matsuzaki%2C+Ibu&rft.date=2024-08-01&rft.issn=0010-4825&rft.volume=178&rft.spage=108774&rft_id=info:doi/10.1016%2Fj.compbiomed.2024.108774&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_compbiomed_2024_108774 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00104825%2Fcov200h.gif |